We are live on
!
Find out more
SAM
Sectoral Asset Management Portfolio holdings
AUM
$121M
1-Year Est. Return
73.47%
This Fund
S&P 500
This Quarter
Est. Return
+10.57%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$2.32B
AUM Growth
+$241M
(+12%)
Cap. Flow
+$64.7M
Cap. Flow
% of AUM
2.79%
Top 10 Holdings %
Top 10 Hldgs %
43.21%
Holding
64
New
9
Increased
30
Reduced
18
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$66.8M |
| 2 |
Celldex Therapeutics
CLDX
|
+$33M |
| 3 |
KERX
Keryx Biopharmaceuticals Inc
KERX
|
+$32.9M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$29M |
| 5 |
Ionis Pharmaceuticals
IONS
|
+$27.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Incyte
INCY
|
+$58.3M |
| 2 |
ARIA
Ariad Pharmaceuticals Inc
ARIA
|
+$55.4M |
| 3 |
Gilead Sciences
GILD
|
+$52.6M |
| 4 |
MDVN
MEDIVATION, INC.
MDVN
|
+$37.8M |
| 5 |
VPHM
VIROPHARMA INC
VPHM
|
+$21.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 89.78% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Biogen
BIIB
$30.4B
| $152M | 6.57% |
544,575
+258,375
| +90% | +$66.8M |
|
|
2
Gilead Sciences
GILD
$167B
| $146M | 6.29% |
1,941,573
-755,114
| -28% | -$52.6M |
|
3
Amgen
AMGN
$198B
| $144M | 6.21% |
1,262,633
-20,359
| -2% | -$2.32M |
|
|
CELG
4
DELISTED
Celgene Corp
CELG
| $119M | 5.15% |
1,412,872
-184,400
| -12% | -$14.6M |
|
5
Vertex Pharmaceuticals
VRTX
$123B
| $91.5M | 3.95% |
1,232,158
-3,597
| -0.3% | -$250K |
|
|
6
Regeneron Pharmaceuticals
REGN
$70.9B
| $76M | 3.28% |
276,000
+101,000
| +58% | +$29M |
|
7
Halozyme
HALO
$9.23B
| $70.5M | 3.04% |
4,701,362
+315,000
| +7% | +$4.05M |
|
8
Innoviva
INVA
$1.6B
| $70.3M | 3.03% |
2,448,726
+36,609
| +2% | +$1.07M |
|
|
SHPG
9
DELISTED
Shire pic
SHPG
| $66.2M | 2.86% |
468,759
+57,173
| +14% | +$7.51M |
|
|
ALXN
10
DELISTED
Alexion Pharmaceuticals
ALXN
| $66M | 2.84% |
496,308
+1,800
| +0.4% | +$216K |
|
|
AGN
11
DELISTED
Allergan Inc
AGN
| $62.4M | 2.69% |
561,333
+127,347
| +29% | +$12.2M |
|
|
12
Incyte
INCY
$23.4B
| $60M | 2.59% |
1,185,260
-1,339,424
| -53% | -$58.3M |
|
13
Viatris
VTRS
$20.1B
| $59.4M | 2.56% |
1,368,707
+181,925
| +15% | +$7.48M |
|
14
Ironwood Pharmaceuticals
IRWD
$635M
| $59M | 2.55% |
6,071,489
+340,470
| +6% | +$3.06M |
|
15
Thermo Fisher Scientific
TMO
$198B
| $57.5M | 2.48% |
516,600
-116,800
| -18% | -$11.6M |
|
16
Merck
MRK
$315B
| $54.8M | 2.36% |
1,147,228
+96,358
| +9% | +$4.4M |
|
|
17
Celldex Therapeutics
CLDX
$2.77B
| $53.9M | 2.33% |
148,513
+85,545
| +136% | +$33M |
|
|
NPSP
18
DELISTED
NPS PHARMACEUTICALS INC
NPSP
| $53.9M | 2.32% |
1,774,919
-308,209
| -15% | -$8.49M |
|
|
AGN
19
DELISTED
Allergan plc
AGN
| $51.6M | 2.23% |
307,150
+104,500
| +52% | +$16.3M |
|
|
IMGN
20
DELISTED
Immunogen Inc
IMGN
| $51.5M | 2.22% |
3,513,282
-139,611
| -4% | -$2.15M |
|
21
Perrigo
PRGO
$1.48B
| $50.2M | 2.17% |
327,268
+96,083
| +42% | +$13.8M |
|
22
BioMarin Pharmaceuticals
BMRN
$11.5B
| $50.2M | 2.17% |
713,806
-8,100
| -1% | -$550K |
|
|
23
Ionis Pharmaceuticals
IONS
$8.99B
| $48.7M | 2.1% |
1,222,401
+781,000
| +177% | +$27.8M |
|
|
GEVA
24
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
| $47.8M | 2.06% |
739,005
+268,055
| +57% | +$15.9M |
|
|
OMED
25
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
| $36M | 1.55% |
1,220,006
+160,527
| +15% | +$2.94M |
|
Similar funds
RIP
CCM
LFWA
FWA
CF
WIM
MW
AFC
Sectoral Asset Management's Q4 2013 Portfolio in Review
As of Q4 2013, Sectoral Asset Management held 64 positions worth $2.32B, up 12% from $2.08B the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Sectoral Asset Management's Q4 2013 filing shows 9 new, 30 increased, 18 reduced and 5 closed positions. Its largest new stake was Keryx Biopharmaceuticals Inc: 2,758,950 shares worth $35.7M. The largest sale was Incyte, an estimated $58.3M.
By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 86% a quarter earlier.
- Sectoral Asset Management's largest Q4 2013 buy was Keryx Biopharmaceuticals Inc: 2,758,950 shares worth $35.7M.
- Sectoral Asset Management added most to Biogen in Q4 2013, an estimated $66.8M increase.
- Sectoral Asset Management's biggest Q4 2013 reduction was Incyte, cutting an estimated $58.3M.
- Sectoral Asset Management fully exited Ariad Pharmaceuticals Inc in Q4 2013, selling an estimated $55.4M.
- Sectoral Asset Management's ten largest holdings make up 43% of its $2.32B portfolio in Q4 2013.
- Sectoral Asset Management opened 9 new positions and closed 5 in Q4 2013.
- Sectoral Asset Management's portfolio value rose 12% quarter-over-quarter to $2.32B.
Based on Sectoral Asset Management's 13F filing for Q4 2013, filed 12 Feb 2014.